#1Proposed tier Unassignedcontextual regulatoryAwaiting human appraisal
Drugs@FDA: FDA-Approved Drugs database
WPF seed · 2026 · Source ID url:https://www.accessdata.fda.gov/scripts/cder/daf/
contextual-regulatory
Scientific intelligence record
Experience 2.0
Growth-hormone fragment analog
Also known as: AOD9604, Anti-Obesity Drug 9604, hGH fragment 177-191 analog
AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to investigate lipolytic and anti-obesity effects while attempting to avoid the broader growth-promoting actions of full-length growth hormone.
Record status
Traceability partial
Last meaningful update: 9/8/2026
Ranked research corpus
27
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
27 matching records · ranked 2026-09-18
Page 1 of 2
WPF seed · 2026 · Source ID url:https://www.accessdata.fda.gov/scripts/cder/daf/
contextual-regulatory
WPF seed · 2026 · PMID 42328738 · DOI 10.1039/d6an00455e
laboratory-mechanistic
Europe PMC · 2026 · Source ID doi:10.20944/preprints202512.1011.v3 · DOI 10.20944/preprints202512.1011.v3
preclinical-animal
WPF seed · 2026 · PMID 41966639 · DOI 10.1007/s40279-026-02437-0
human-interventional
WPF seed · 2026 · Source ID url:https://www.wada-ama.org/en/prohibited-list
contextual-regulatory
WPF seed · 2026 · PMID 42395176 · DOI 10.3389/fendo.2026.1822475
laboratory-mechanistic
WPF seed · 2026 · PMID 41490200 · DOI 10.5435/JAAOSGlobal-D-25-00236
laboratory-mechanistic
Europe PMC · 2025 · Source ID doi:10.20944/preprints202512.1011.v1 · DOI 10.20944/preprints202512.1011.v1
preclinical-animal
WPF seed · 2022 · PMID 35783198 · DOI 10.2147/DDDT.S367586
laboratory-mechanistic
WPF seed · 2016 · PMID 26578461 · DOI 10.1002/jssc.201501060
laboratory-mechanistic
WPF seed · 2015 · PMID 25208511 · DOI 10.1002/dta.1715
laboratory-mechanistic
WPF seed · 2015 · PMID 26275694
preclinical-animal
WPF seed · 2014 · PMID 24906629 · DOI 10.1016/j.jpba.2014.05.020
laboratory-mechanistic
WPF seed · 2014 · PMID 25382550 · DOI 10.1586/14789450.2014.965159
laboratory-mechanistic
WPF seed · 2014 · PMID 24976118 · DOI 10.1002/dta.1687
human-observational
WPF seed · 2013 · PMID 24124033 · DOI 10.1002/dta.1557
laboratory-mechanistic
WPF seed · 2012 · PMID 22435392 · DOI 10.2174/187221412800604644
laboratory-mechanistic
WPF seed · 2007 · PMID 17971763
laboratory-mechanistic
WPF seed · 2006 · PMID 16625817
laboratory-mechanistic
WPF seed · 2006 · PMID 16931496 · DOI 10.1038/oby.2006.294
human-interventional
WPF seed · 2005 · PMID 15834452
human-interventional
WPF seed · 2004 · PMID 15134286
human-interventional
WPF seed · 2003 · PMID 14571286
human-interventional
WPF seed · 2003 · PMID 14685303
human-interventional
WPF seed · 2001 · PMID 11673763 · DOI 10.1038/sj.ijo.0801740
preclinical-animal
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.
European Medicines Agency medicines databaseNo FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.
Drugs@FDA: FDA-Approved DrugsAOD-9604 evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
Cyclic/disulfide identity is explicit; the schematic is not a determined fold.
Sources: NIH PubChem — AOD-9604 · reviewed 2026-09-17
APA
World Peptide Foundation. (n.d.). AOD-9604 — Peptide Scientific Intelligence. World Peptide Foundation. (Reviewed September 8, 2026.) https://www.worldpeptidefoundation.org/directory/aod-9604
AMA / Vancouver
World Peptide Foundation. AOD-9604 — Peptide Scientific Intelligence. World Peptide Foundation website. Reviewed September 8, 2026. https://www.worldpeptidefoundation.org/directory/aod-9604
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
5
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
27
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
5
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
AOD-9604 no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasThis score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2000 · study · Temporal status not established
peer_reviewed_research
2001 · study · Temporal status not established
peer_reviewed_research
2001 · study · Temporal status not established
peer_reviewed_research
2003 · study · Temporal status not established
peer_reviewed_research
2003 · study · Temporal status not established
peer_reviewed_research
2004 · study · Temporal status not established
peer_reviewed_research
2005 · study · Temporal status not established
peer_reviewed_research
2006 · study · Temporal status not established
peer_reviewed_research
2006 · study · Temporal status not established
peer_reviewed_research
2007 · study · Temporal status not established
peer_reviewed_research
2012 · study · Temporal status not established
peer_reviewed_research
2013 · study · Temporal status not established
peer_reviewed_research
2014 · study · Temporal status not established
peer_reviewed_research
2014 · study · Temporal status not established
peer_reviewed_research
2014 · study · Temporal status not established
peer_reviewed_research
2015 · study · Temporal status not established
peer_reviewed_research
2015 · study · Temporal status not established
peer_reviewed_research
2016 · study · Temporal status not established
peer_reviewed_research
2022 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · study · Temporal status not established
peer_reviewed_research
2026 · regulatory · Temporal status not established
European Union (EMA)
2026 · regulatory · Temporal status not established
United States (FDA)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
4 represented evidence records
Years represented: 2013, 2014, 2016
Publishing organizations appearing in records: peer_reviewed_research
4 represented evidence records
Years represented: 2013, 2014, 2016
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2013, 2014, 2016
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2003, 2005
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2000, 2001
Publishing organizations appearing in records: peer_reviewed_research
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 5 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the AOD-9604 evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union (EMA)
Regulator: EMA
As of: 9/8/2026 · Temporal status not established
United States (FDA)
Regulator: FDA
As of: 9/8/2026 · Temporal status not established
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:24:58 AM
23 of 27 screening records carry a machine-proposed evidence-strength grade; the remainder are unassigned pending further review.
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This issue focuses on the following selection of drugs: ABX-IL-8, Acclaim, adalimumab, AGI-1067, alagebrium chloride, alemtuzumab, Alequel, Androgel, anti-IL-12 MAb, AOD-9604, aripiprazole, atomoxetine hydrochloride; Biphasic insulin aspart, bosentan, botulinum toxi …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-129 …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Metabolic is developing AOD-9604 for the potential treatment of obesity. By February 2002, phase IIa trials were underway....
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Drugs that improve adipose tissue function or fatty acid metabolism (e.g., AOD9604) also are in clinical trials. Some currently available medications may reduce metabolic complications without treating obesity per se (e.g., acipimox, pioglitazone). ...
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This issue focuses on the following selection of drugs: Abetimus sodium, adefovir dipivoxil, AGI-1067, alefacept, alemtuzumab, ALVAC-p53, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, Anti-CTLA-4 Mab, AOD-9604, apafant, aprinocarsen sodium, ar …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This issue focuses on the following selection of drugs: Abarelix, ABX-EGF, ademetionine, agomelatine, AMGN-0007, 9-aminocamptothecin, AN-9, anecortave acetate, anidulafungin, AOD-9604, apolizumab, apomate, L-arginine hydrochloride, arzoxifene hydrochloride; Bevacizu …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This peer-reviewed source examines Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
OBJECTIVE: To observe the chronic effects of human growth hormone (hGH) and AOD9604 (a C-terminal fragment of hGH) on body weight, energy balance, and substrate oxidation rates in obese (ob/ob) and lean C57BL/6Jmice. ...CONCLUSIONS: Both hGH and its C-termina …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
A synthetic analogue (AOD9604) of the lipolytic domain of human growth hormone (hGH) has been studied for its metabolic actions in obese Zucker rats. ...The adipose tissues of the AOD9604--treated animals were found to have an increase in lipolytic act …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Both human GH (hGH) and a lipolytic fragment (AOD9604) synthesized from its C-terminus are capable of inducing weight loss and increasing lipolytic sensitivity following long-term treatment in mice. ...However, in an acute experiment, AOD9604 was capab …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Weekly injections of 0.6 mL saline (Group 1), 6 mg HA (Group 2), 0.25 mg AOD9604 (Group 3), and 0.25 mg AOD9604 with 6 mg HA (Group 4) were administered for 4-7 weeks after the first intra-articular collagenase injection. ...The lameness period in Group 1 was signif …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD- …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Stability studies showed that all compounds were stable (variation lower than 15%) for at least two months at -20 C in all the blood matrices considered. At 4 and 22 C, alexamorelin, AOD9604, buserelin, hGH 176-191, kisspeptin-10 and LHRH were extensively degraded after …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The new antiobesity drugs under clinical development include: 1) agents that affect neurotransmitters in the central nervous system, including noradrenaline and dopamine reuptake inhibitors (bupropion, radafaxine), selective 5HT2C receptor agonists (lorcaserin), and selective 5HT …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Among these compounds, low- and high-molecular mass substances of peptidic (e.g. modified insulin-like growth factor-1, TB-500, hematide/peginesatide, growth hormone releasing peptides, AOD-9604, etc.) and non-peptidic (selective androgen recept …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This peer-reviewed source examines AOD-9604 does not influence the WADA hGH isoform immunoassay.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. The agents most commonly encountered in clinical practice and online self-ad …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Several peptides <2 kDa with performance-enhancing properties are covered by the list of prohibited substances of the World Anti-Doping Agency including Desmopressin, LH-RH, Buserelin, Triptorelin, Leuprolide, GHRP-1, GHRP-2, GHRP-3, GHRP-4, GHRP-5,GHRP-6, Alexamorelin, Ipamor …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
These allow detecting the misuse of peptidic compounds of lower (such as growth hormone-releasing peptides, ARA-290, TB-500, AOD-9604, CJC-1295, desmopressin, luteinizing hormone-releasing hormones, synacthen, etc.), intermediate (e.g., insulins …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In this review, we discuss the FDA approved anti-obesity drugs and recent patents which include phentermine/topiramate, pramlintide, lorcaserin, AOD9604, oleoyl-estrone, trk-beta antagonists and melanin concentrating hormone that can reduce adiposity at the molecula …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
AOD9604 is a peptide consisting of the C-terminal fragment of human growth hormone from amino acids 177-191 with an additional tyrosine residue at the N-terminus of the peptide. It is reported to mimic the lipolytic properties of growth hormone …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
OBJECTIVE: To evaluate the anticancer efficacy of Chitosan nanoparticles loaded with human growth hormone hGH fragment 176-191 peptide plus the clinical chemotherapeutic doxorubicin in comparison with Chitosan loaded with doxorubicin alone. METH …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety s …
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Official international sport source used to classify growth-hormone fragments and related substances in anti-doping rules.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Official FDA database used to verify whether an AOD-9604 drug product or indication has received FDA approval.
2 represented evidence records
Years represented: 2000, 2001
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2000, 2001
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2003, 2005
Publishing organizations appearing in records: peer_reviewed_research
3 represented evidence records
Years represented: 2003, 2005
Publishing organizations appearing in records: peer_reviewed_research
2 represented evidence records
Years represented: 2013, 2016
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2012
Publishing organizations appearing in records: peer_reviewed_research
1 represented evidence record
Years represented: 2022
Publishing organizations appearing in records: peer_reviewed_research